DNA Script partners with Premas Life Sciences to meet demand for same-day Enzymatic DNA Synthesis

DNA Script has reached a distribution agreement with Premas Life Sciences. This partnership expands DNA Script’s footprint and provides sales and support for the syntax System DNA printer in labs in India, DNA Script said in a statement.

APAC is experiencing significant genomic research growth, spurring increased demand for synthetic biology tools, including DNA Script’s syntax system. As the world’s first commercial benchtop enzymatic DNA printer, the syntax system gives labs complete control over their oligo production, alleviating the need to wait for deliveries from third-party DNA service providers and dramatically accelerating their research, the statement added.

The syntax system printer is the only commercial DNA-manufacturing technology that utilises the power of Enzymatic DNA Synthesis (EDS), which produces synthetic DNA without the toxic reagents and hazardous waste associated with older DNA-printing methods. Companies can now iterate in a matter of hours by printing ready-to-use oligos in-house instead of waiting days for outsourced service providers to deliver the DNA needed, it concluded.